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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.07.013Objectives: Elevated pulmonary vascular resistance may contribute to late Fontan
circulation failure but is difficult to assess in such patients. Our aims were to assess
outcomes of patients with failed Fontan circulation after heart transplantation and to
determine whether elevated pulmonary vascular resistance might have contributed
to the failure.
Methods: Fifteen patients (14 Fontan circulations, 1 Kawashima circulation) under-
went transplantation. The most common indication was ventricular dysfunction
(mean ventricular end-diastolic pressure 12.5 mm Hg). Patients with early failures
(n  4) required transplantation less than 1 year after the Fontan operation. Those
with late failures (n  11) underwent transplantation at least 1 year after the Fontan
operation. Mean age at transplantation was 11.6 years. Mean Fontan-transplantation
interval was 7.4 years. Mean pulmonary arterial pressure, transpulmonary gradient,
and pulmonary vascular resistance before and after transplantation were assessed.
Paired t tests of variable differences were used to compare variables. Survival was
estimated by the Kaplan-Meier method.
Results: In-hospital mortality was 7%. There were 2 late events (1 death, 1
retransplantation) related to compliance or rejection issues. Graft survivals were
93%, 82%, and 82% at 3, 5, and 7 years, respectively. Posttransplantation pulmo-
nary vascular resistance was elevated (2.0 Wood units · m2) in 11 of 14 survivors
past initial hospitalization (mean 3.3  1.7 Wood units · m2). Only patients with
early Fontan failures (3 of 4) had normal posttransplantation pulmonary vascular
resistance. In paired comparisons, posttransplantation transpulmonary gradient was
increased by a mean of 6.8 mm Hg (P  .0001) relative to pretransplantation value.
Conclusions: Outcomes after heart transplantation for failed Fontan circulation were
good. Mild-to-moderate pulmonary vascular disease was evident after heart trans-
plantation for late failure. Elevated pulmonary vascular resistance is a likely
contributor to Fontan circulation failure.
Outcomes for recent modifications of the Fontan operation haveshown significant improvement1-3; however, the durability of thepalliated single-ventricle circulation remains limited.1,4-6 Mecha-nisms that contribute to late Fontan circulation attrition includeloss of sinus rhythm, atrial tachyarrhythmia, suboptimal flowdynamics, pulmonary venous compression, atrioventricular valve
regurgitation, subaortic obstruction, and progressive ventricular failure.7-9 Pulmo-
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Dnary vascular disease clearly increases Fontan operative risk
and the risk of early failure.10 In contrast, the impact of the
pulmonary vascular bed on medium- and long-term out-
comes after Fontan surgery has not been defined. It is
possible that the Fontan state itself may induce the devel-
opment or progression of pulmonary vascular disease, thus
negatively influencing long-term outcome.5 Low cardiac
output, multiple sources of pulmonary blood flow, presence
of pulmonary arteriovenous malformations (PAVMs), and
other unique factors limit the accuracy of pulmonary vas-
cular resistance (PVR) determination in patients with failing
Fontan circulations.11 Consequently, it is difficult to quan-
TABLE 1. Patient diagnoses and palliation
Patient Diagnosis
Early Fontan failures
1 TA, PA, Bilateral SVC
2 Asplenia, situs inversus, TA, PS, bila
SVC
3 Double-inlet left ventricle
4 Double-outlet right ventricle, MA, VS
Mean  SD
Late Fontan failures
1 Polysplenia, unbalanced atrioventric
septal defect, PA, interrupted infe
vena cava with hemiazygous
continuation, bilateral SVC
2 Single ventricle, PA, dextrocardia
3 TA, PA
4 TA, PA
5 MA, PS, D-TGA, VSD
6 PA-IVS
7 TA, VSD, PS
8 TA, VSD, PS
9 Polysplenia, MA, VSD, D-TGA, bilater
SVC
10 TA, VSD
11 PA-IVS
Mean  SD
Total mean  SD (n  15)
Semicolons delineate separate surgical procedures. TA, Tricuspid atresia;
shunt; BCPS, bidirectional cavopulmonary shunt; EC-F, extracardiac cond
atresia; VSD, ventricular septal defect; LT-F, lateral tunnel Fontan; CAPS,
aortopulmonary shunt; D-TGA, dextrotransposition of the great arteries; P
Taussig shunt; RARV-F, right atrial–right ventricle Fontan connection.
*Measured from date of first Fontan operation to transplantation.tify pulmonary vascular disease in such patients, and the
694 The Journal of Thoracic and Cardiovascular Surgery ● Noveinfluence of pulmonary vascular disease on late Fontan
circulation failure is unknown.
Heart transplantation is the only option after failed sin-
gle-ventricle palliation, provided that failure is not due to
correctable flow dynamics or arrhythmias. There have been
few studies reporting outcomes in patients undergoing
transplantation after a Fontan operation.11-15 Small patient
numbers, limited follow-up, and substantial surgical mor-
tality characterize these reports. Because right ventricle–
pulmonary artery coupling is inherently absent in the Fontan
circulation, it is tempting to assume that PVR in the patient
with failing Fontan circulation must fall within safely trans-
Surgical history
Fontan
age (y)
Failure
interval (y)*
MBT; bilateral BCPS; EC-F, coronary
artery bypass graft, left ventricular
assist device
3.8 0.025
MBT; bilateral BCPS; EC-F 3.4 0.38
PAB; BCPS, pulmonary artery ligation,
EC-F
4 0.39
PAB; LT-F 2.6 0.68
3.4  0.6 0.37  0.27
MBT  2; Kawashima 3.3 4.2
MBT; CAPS; AP-F 3.8 4.2
MBT; LT-F 2 6.1
WAPS; CAPS; MBT; AP-F; BCPS;
revised AP-F
6.5 7.2
MBT, LT-F, revised LT-F 4 8.2
CBT, classic cavopulmonary shunt,
AP-F
1.3 8.3
WAPS; LT-F 14.7 10.6
CBT; RARV-F; revised RARV-F 6.7 10.9
PAB; AP-F 1.9 11.6
PAB; RARV-F; revised RARV-F 3.5 17.2
Formalinization of patent ductus
arteriosus; MBT  2; AP-F; BCPS,
EC-F
2.6 21.1
4.6  3.8 10.0  5.2
4.3  3.2 7.4  6.2
lmonary atresia; SVC, superior vena cava; MBT, modified Blalock-Taussig
ntan; PS, pulmonary stenosis; PAB, pulmonary artery banding; MA, mitral
al aortopulmonary shunt; AP-F, atriopulmonary Fontan; WAPS, Waterston
, pulmonary atresia with intact ventricular septum; CBT, classic Blalock-teral
D
ular
rior
al
PA, pu
uit Fo
centr
A-IVSplantable limits. However, these reports indicate a substan-
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Dtial incidence of right ventricular failure after transplanta-
tion, suggesting that PVR may be elevated in some patients.
In this study we postulated that patients with failed Fontan
circulations who underwent conversion to biventricular phys-
iology with heart transplantation would provide an ideal cohort
to investigate whether pulmonary vascular disease is present in
patients with failing single-ventricle circulation. The specific
aims of this report were as follows: to assess the outcomes of
patients undergoing heart transplantation in our center for
failing Fontan circulations and to determine whether pulmo-
nary vascular disease was present in these patients.
Patients and Methods
Patient Population
All patients who underwent transplantation in our center through
December 31, 2002, for failing Fontan and Kawashima circula-
tions were identified. Medical records were examined retrospec-
tively, and a separate research database was compiled, eliminating
all identifying information. The Colorado Multiple Institution Re-
view Board approved this study. Fifteen patients (14 Fontan cir-
TABLE 2. Transplantation indications and outcomes
Patient Transplant indications
Early Fontan failures
1 Ventricular failure (left coronary artery injury
at extracardiac conduit Fontan, left
ventricular assist device)
2 Ventricular dysfunction, atrioventricular
valve regurgitation
3 Ventricular dysfunction
4 Ventricular dysfunction
Mean  SD
Late Fontan failures
1† Ventricular dysfunction, cyanosis, PAVMs
2 PLE
3 Ventricular dysfunction, right pulmonary vein
obstruction
4 Ventricular dysfunction, functional single
lung
5 PLE, atrial flutter
6 Ventricular dysfunction, cardiogenic
cirrhosis
7 Ventricular dysfunction
8 Ventricular dysfunction, PLE, atrial flutter
9 Ventricular dysfunction, PLE, atrial flutter
10 Ventricular dysfunction
11 Ventricular dysfunction, PAVMs, atrial flutter
Mean  SD
Total mean  SD (n  15)
UNOS, United Network for Organ Sharing; VEDP, ventricular end-diastolic
*Pretransplantation catheterization.
†Kawashima.
‡In-hospital death.culations, 1 Kawashima circulation) underwent transplantation.
The Journal of ThoraciThere were no deaths among similar patients on the waiting list.
Table 1 lists diagnoses and surgical summaries of transplant re-
cipients. Ventricular dominance was left in 10 patients and right in
5. Fontan modifications at transplantation included 5 lateral tun-
nels, 4 extracardiac conduits, 3 atriopulmonary connections, and 2
right atrial–right ventricular conduits (n  14 total). Fontan path-
way fenestration was performed in only 1 patient, and the fenes-
tration closed spontaneously before pretransplantation assessment.
The mean number of previous cardiac procedures was 3.5  1.5.
Table 1 segregates patients by time to palliation failure (early
1 year vs late 1 year). Transplantation indications, United
Network for Organ Sharing status at the time of transplantation,
and outcomes are given in Table 2. Ventricular dysfunction was
the most common indication. Pretransplantation ventricular end-
diastolic pressure was elevated (12 mm Hg) in 8 of 13 patients
in whom it was measured. One patient with late Fontan circulation
failure had protein-losing enteropathy (PLE) only. Three patients
with late Fontan circulation failure had both PLE and intermittent
atrial flutter. A fourth patient with late Fontan circulation failure
had both atrial flutter and PAVMs. No other patients had known
atrial tachyarrhythmia. PAVMs were documented in the patient
S
s
VEDP*
(mm Hg)
Transplant
age (y)
Follow-up
(y) Status
ND 3.8 3.2 Alive
15 3.8 3.6 Alive
16 4.4 3.4 Alive
9 3.3 6.5 Alive
13.3 3.8 3.8  0.5 4.1 1.6
14 7.5 9.2 Alive
9 8.0 8.2 Alive
10 8.1 7.8 Dead
ND 13.8 4.5 ReTx
8 12.1 4.2 Alive
7 9.7 11.1 Alive
12 25.2 12.8 Alive
16 17.6 0.5 Dead‡
12 13.5 7.8 Alive
12 20.6 3.2 Alive
18 23.6 2.3 Alive
11.8 3.5 14.5  6.4 6.5 3.9
12.5 7.8 11.6 7.3 5.9 3.5
sure; ND, not determined; ReTx, repeat transplantation.UNO
statu
1a
1a
1a
1a
1b
1b
2
1b
1b
1b
2
2
1b
1a
1b
preswith Kawashima circulation failure.
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All recipients were matched with ABO-compatible donors. Donor
hearts were preserved with 4°C Roe solution, and additional donor
tissue was procured whenever possible to facilitate systemic ve-
nous and pulmonary artery reconstruction at transplantation. Apro-
tinin was used routinely. Posttransplantation management and
immune suppression were as previously reported by our institu-
tion.16 The posttransplantation rejection surveillance protocol in
our center is as follows. Heart catheterization with endomyocardial
biopsy and coronary artery assessment is performed for rejection
surveillance within 12 months of transplantation. Patients with
acute rejection episodes more than 3 months after transplantation
undergo surveillance catheterization at 3 to 6 months after the
rejection episode. Coronary angiography and intravascular ultra-
sound are used to screen for graft coronary artery disease (CAD).
Pulmonary Hemodynamics
Variables of pulmonary vascular status considered were mean pul-
monary artery pressure (PAP), transpulmonary gradient (TPG), and
PVR. Available data were collected from catheterizations before and
after transplantation. In 2 patients branch pulmonary artery stenoses
were corrected with balloon angioplasty before pretransplantation
hemodynamic evaluation. No other patients had branch pulmonary
stenosis identified at pretransplantation evaluation. Posttransplanta-
tion comparisons of variables were determined from data obtained at
the time of first routine surveillance catheterization. Catheterizations
performed for suspected rejection and studies demonstrating active
rejection were excluded. All catheterizations were performed with
local anesthesia, conscious sedation as required, and spontaneous
ventilation (arterial PCO2 range 35-45 mm Hg) on room air. Because
the pretransplantation measurement of pulmonary blood flow is sub-
ject to significant error in the patient population under study, PVR was
not routinely assessed during pretransplantation evaluation. The pri-
mary factor considered in the pretransplantation assessment of pul-
monary vascular disease was TPG. All surviving patients had PVR
measured at posttransplantation assessment. Previously published
normal values were used for the assessment of pulmonary hemody-
Figure 1. Kaplan-Meier– estimated survival of all patients.
Dashed lines indicate 95% confidence limits. f/u, Follow-up.namics.17,18
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In-hospital mortality was defined as death before discharge from
the hospital after transplantation. Intensive care and hospital stays
were determined from the time of transplantation. Pretransplanta-
tion versus posttransplantation mean PAP, TPG, and PVR values
were compared with paired t tests of mean differences to test the
null hypothesis that the difference was zero. Paired comparisons
were made for the entire patient population, and patients with late
Fontan circulation failure were also compared separately. For all
comparisons, patients missing paired data points and those with
split sources of pulmonary blood flow before transplantation were
excluded. The mean follow-up was 5.9 years (range 0.5-12.8
years) and was complete. Graft survival was estimated by the
Kaplan-Meier method.
Results
Transplant Procedures
Median waiting list time was 28 days (range 2-669 days).
The mean total graft ischemia time was 248  68 minutes,
and mean cardiopulmonary bypass time was 169  56
minutes. Bicaval anastomotic techniques were used in 14
cases, and bilateral superior vena cava connections were
necessary in 3 cases.
Transplantation Hospital Course
Complications occurred in 8 patients and were multiple in 6
cases. Complications resulted in major morbidity in 6 cases.
Median posttransplantation intensive care and hospital stays
were 8 days (range 3-148 days ) and 17 days (range 5-179
days). One in-hospital death (7%) occurred in a patient with
late Fontan circulation failure who had hepatic failure de-
velop and underwent liver transplantation on postoperative
day 30. This patient died of multiple organ failure on
post–heart transplantation day 179. Pathologic evaluation
of the explanted liver indicated occult cardiogenic cirrhosis.
Late Outcomes
Two late graft failures occurred, at 4.5 years (resulting in
retransplantation) and 7.8 years (resulting in death). Esti-
mated graft survivals at 3, 5, and 7 years were 93%, 82%,
and 82% (Figure 1). Both late graft failures were rejection
related, and adolescent noncompliance was a major factor in
each. Pathologic assessments revealed severe graft CAD in
1 case and moderate graft CAD in the other. Both cases
evidenced myocardial injury from chronic rejection and
severe acute rejection.
All 12 surviving patients were in New York Heart As-
sociation functional class I at most recent follow-up exam-
ination. Surveillance coronary evaluations revealed no evi-
dence of graft CAD in 10 patients at a mean time from
transplantation of 3.4 2.2 years. Mild CAD was present in
2 patients on studies performed 5.7 and 6.6 years posttrans-
plantation. One patient was successfully treated for post-
transplantation lymphoproliferative disease. One patient
(patient 2 in the early Fontan group) required reoperation at
mber 2004
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D15 months for pulmonary venous obstruction. This patient
had situs inversus with bilateral superior caval veins and
underwent transplantation with the method previously re-
ported by Vricella and associates.19 At reoperation, stricture
of the left atrial anastomosis was identified and corrected
with a “sutureless” pericardial augmentation. All surviving
patients with PAVMs (n  2) and PLE (n  3) had
resolution within 6 months of transplantation.
Pulmonary Hemodynamics
Pulmonary hemodynamic evaluations are summarized in
Table 3. Posttransplantation mean PAP was elevated (18
mm Hg) in 8 patients. Seven of 10 surviving patients with
late Fontan circulation failure had elevated mean PAP
(range 19-24 mm Hg), and the 3 patients in this group with
normal mean PAP were all at the upper limit of normal (18
mm Hg). In contrast, only 1 of the 4 patients with early
Fontan circulation failure had elevated mean PAP after
transplantation. Posttransplantation TPG was elevated (9
mm Hg) in 13 patients. All patients with late Fontan circu-
lation failure had elevated posttransplantation TPG (range
TABLE 3. Pretransplantation and posttransplantation pulm
Early Fontan
n Mean  SD
Mean PAP (mm Hg)
Pretransplantation 4 17.0 5.0
Posttransplantation 4 17.8 4.0
Mean TPG (mm Hg)
Pretransplantation 4 6.0 2.0
Posttransplantation 4 10.5 1.7
Mean PVR (Wood units · m2)
Pretransplantation 4 2.1 1.4
Posttransplantation 4 2.0 0.4
TABLE 4. Paired pretransplantation versus posttransplanta
Variable n Before
All patients
PAP (mm Hg) 13 17.0 3.7
TPG (mm Hg) 12 5.3 2.3
PVR (Wood units · m2) 6 1.8  1.1
Late Fontan failures
PAP (mm Hg) 9 17.0 3.4
TPG (mm Hg) 8 4.9 2.5
PVR (Wood units · m2) 3 1.5  0.9
Comparisons made with t test of the difference in paired data, testing the n
failure group was excluded from comparisons because of split pulmonary a
pulmonary artery and atriopulmonary Fontan with left pulmonary artery).10-16 mm Hg). Posttransplantation PVR was elevated in all
The Journal of Thoraci10 surviving patients with late Fontan circulation failure
(range 2.8-5.4 Wood units · m2). Posttransplantation PVR
was mildly elevated in only 1 of the 4 patients with early
Fontan circulation failure. These data indicate that patients
with late-failing Fontan circulations had a high prevalence
of underlying mild-to-moderate pulmonary vascular dis-
ease.
Table 4 presents paired pretransplantation versus post-
transplantation comparisons (includes only patients with
variables measured at pretransplantation and posttransplan-
tation catheterization). When all patients with paired data
were considered, TPG increased by a mean of 6.8 mm Hg
after transplantation (P  .001). Mean PAP averaged 2.7
mm Hg higher after transplantation, but this increase was of
marginal significance (P  .064). Findings were similar
when the late Fontan group was analyzed separately, with a
marginally significant increase in mean PAP (3.6 mm Hg, P
 .057) and an increase in TPG of 7.9 mm Hg (P  .0004).
Our institutional bias is that pulmonary blood flow cannot
be accurately measured in the failing Fontan state.11 PVR
y hemodynamics
Late Fontan All patients
n Mean  SD n Mean  SD
11 16.7 3.3 15 16.8  3.6
10 20.8 2.4 14 19.9  3.3
10 4.5 2.8 14 4.9  2.8
10 12.8 2.0 14 12.1  1.4
5 1.5  0.7 8 1.7  0.6
10 3.8 0.8 14 3.3  1.7
pulmonary hemodynamic comparisons
After
Mean
difference SD P value
19.7 3.3 2.7 4.8 .064
12.0 2.1 6.8 3.5 .0001
2.7 1.0 0.8 1.7 .296
20.6 2.5 3.6 4.8 .057
12.8 2.0 7.9 3.6 .0004
3.5 0.7 2.0 1.5 .155
pothesis that the difference in mean values was 0. Patient 6 in late Fontan
circulation before transplantation (classic cavopulmonary shunt with rightonartion
ull hy
rterywas not measured during the pretransplantation evaluation
c and Cardiovascular Surgery ● Volume 128, Number 5 697
Surgery for Congenital Heart Disease Mitchell et al
CH
Din 7 patients. Consequently, paired pretransplantation and
posttransplantation PVR data were limited, and no differ-
ences were identified for the entire population or the late
Fontan failure group. However, TPGs that increased to
pathologic levels after transplantation are consistent with
the restoration of normal pulmonary blood flow in the
presence of mild-to-moderate pulmonary vascular disease.
Thus, our data indicate that “normal” pulmonary hemody-
namic values measured in the failing Fontan circulation do
not necessarily exclude the presence of pulmonary vascular
disease.
Discussion
Our findings indicate that heart transplantation is effective
therapy with good early and medium-term outcomes for
patients with failing Fontan circulations. These results also
provide clinical evidence that patients with late-failing Fon-
tan circulations had a high incidence of mild-to-moderate
pulmonary vascular disease. It is therefore likely that pul-
monary vascular disease contributed to Fontan failure in
these patients.
We agree with Carey and colleagues11 that measure-
ments of pulmonary blood flow in the patient with a failing
Fontan circulation are unreliable and that the calculation of
a normal PVR in these patients does not exclude pulmonary
vascular disease. The elevated TPGs observed at posttrans-
plantation evaluation indicate that one also cannot use nor-
mal values of this parameter in the pretransplantation as-
sessment of pulmonary hemodynamics without significantly
underestimating pulmonary vascular disease in these pa-
tients. The posttransplantation increase in TPG is explained
by the low cardiac output and limited pulmonary blood flow
present before transplantation in the failing patient. After
transplantation, the increase in TPG to pathologic levels
reflects a fixed element of PVR that was unmasked with the
introduction of normal pulmonary blood flow. Only one
patient in this series had acute graft failure (Tables 1 and 2,
patient 10 of the late Fontan group), primarily as a result of
cold injury. The donor heart was packed with excessive ice,
and the infundibular free wall of the right ventricle was
frozen solid. This patient survived with a short period of
biventricular assistance. The magnitude of pulmonary vas-
cular disease was therefore not sufficient to precipitate
lethal acute graft failure in these patients.
Even modest increases in PVR are likely to have a
negative impact on Fontan circulation longevity, because
the Fontan pathway places the pulmonary capillary bed in
series with the systemic and splanchnic capillary beds.5,20
This study suggests but does not verify a causal relationship
between the long-term presence of the Fontan circulation
and the development or progression of pulmonary vascular
disease. Serial assessments of PVR during the Fontan state
would be necessary to demonstrate that the Fontan circula-
698 The Journal of Thoracic and Cardiovascular Surgery ● Novetion itself promotes increased PVR. However, as noted
previously, we and others do not believe that PVR can be
reliably measured in the failing Fontan circulation,11 and
proof that the Fontan circulation promotes increased PVR is
therefore elusive.
Other factors may explain the presence of pulmonary
vascular disease in our group with late Fontan circulation
failure. Two early patients with Fontan circulation failure
underwent systemic-pulmonary shunts for durations of 6
and 12 months before bidirectional cavopulmonary shunt
procedures, whereas 8 of the 11 patients with late failure of
Fontan circulation underwent one or more palliative sys-
temic-pulmonary shunt procedures that were in place for
durations ranging from 6 months to 124 months. In addition,
no patient in the late Fontan failure group underwent a
bidirectional superior cavopulmonary shunt before the Fon-
tan operation, whereas 3 of 4 patients with early Fontan
circulation failure underwent bidirectional superior cavo-
pulmonary shunt before the Fontan operation. Thus, inade-
quate protection of the pulmonary vasculature before the
Fontan operation could account for the abnormal PVR ob-
served after transplantation in the late Fontan failure group.
However, the fact that the late failure Fontan group dem-
onstrated reasonable palliation for several years before
transplantation (range 4.2-21.1 years) suggests that signifi-
cant pulmonary vascular disease was not present before
Fontan palliation in this group. It is also possible that
transplantation or immunosuppressive medications required
after transplantation might account for our findings, but the
lower posttransplantation PAP and TPG and the normal
PVR observed after transplantation in the early Fontan
failure group argue against this explanation.
There are several mechanisms by which the Fontan cir-
culation may increase PVR. Many investigators have re-
ported catastrophic thromboembolic events in patients with
Fontan circulations.21 Less evident chronic microemboli
could lead to progressive development of increased PVR. In
the normal circulation, a significant portion of the energy
transmitted to the pulmonary artery by right ventricular
ejection is required to maintain patency of the distal pul-
monary vascular bed.5,22 de Leval5 has proposed that the
lower-energy pulmonary circulation inherent in the Fontan
circuit effectively increases pulmonary vascular impedance,
therefore increasing PVR. Elevated pulmonary lymphatic
pressure from transmission of increased central venous
pressure in the Fontan state could also increase PVR be-
cause of pulmonary edema.5
Congenital heart disease remains the most powerful risk
factor for death within 1 year of transplantation in the
pediatric age group.23 Patients with previous Fontan oper-
ations represent one of the most challenging subgroups
requiring transplantation. Our results compare favorably
with other series (mortality range 14%-66%).11-15 Hemor-
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Drhage and donor graft failure were the primary causes of
early mortality in these reports. Pulmonary vascular disease
may have contributed to early deaths reported by other
centers. Lengthy cardiopulmonary bypass times and large
transfusion requirements typical with such patients may
have acutely potentiated significant underlying pulmonary
vascular disease, resulting in acute graft failure. For this
reason we recommend avoidance of undersized and mar-
ginal donors in these cases.
Medium-term survival in our series was relatively good.
Unfortunately, noncompliance with immunosuppression had a
significant impact on late outcomes in our adolescent patients,
and graft rejection will doubtless lead to continued attrition.
Consequently, heart transplantation should be the treatment of
last resort in patients with failing Fontan circulations. Patients
with hemodynamically suboptimal Fontan connections should
undergo Fontan revision, provided that ventricular dysfunction
can be attributed to correctable anatomic or rhythm-related
issues.24-26 Mavroudis and colleagues26 have demonstrated
superb results for Fontan revision combined with antiarrhyth-
mia surgery in patients with atrial tachyarrhythmias. However,
their series included no patients with PLE. These authors have
also suggested that patients with significant ventricular dys-
function evidenced by a ventricular end-diastolic pressure
greater than 12 mm Hg are at increased risk for combined
Fontan conversion and maze procedure. In our series there
were 4 patients with known atrial tachyarrhythmias (Table
patients 2, 5, 8, 9, and 11 in the late failure group). Three of
these patients also had PLE. The fourth patient had persisting
severe PAVMs after narrowly surviving conversion to a total
cavopulmonary connection (without antiarrhythmia surgery) at
another institution 1 year before transplantation. Patient 8 in
the late failure group (Tables 1 and 2) had PLE and was the
only in-hospital death in our series. The other 3 patients with
atrial arrhythmias had resolution of PLE and PAVMs after
transplantation. In our view, patients with significant ventric-
ular dysfunction (ventricular end-diastolic pressure 12 mm
Hg) and patients with PLE are at high risk when undergoing
Fontan revision with or without antiarrhythmia surgery and are
probably better served by transplantation.15,26
In summary, this study demonstrates that heart transplan-
tation is effective treatment for patients with end-stage heart
disease with failed Fontan circulations. Morbidity in this
patient population is considerable, but good early and me-
dium-term outcomes can be achieved in this challenging
subgroup of patients with congenital heart disease. As with
all patients requiring heart transplantation, long-term sur-
vival is limited by rejection. This study also demonstrates
that underlying pulmonary vascular disease becomes appar-
ent after heart transplantation in patients with late-failing
Fontan circulations. Further study is required to delineate
whether the Fontan circulation itself induces pulmonary
The Journal of Thoracivascular disease and to asses the impact this process may
have on Fontan attrition.
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Discussion
Dr Carl L. Backer (Chicago, Ill). I congratulate Mitchell and
coworkers from Denver on their outstanding results with heart
transplantation in patients with a failed Fontan circulation. These
patients have usually had at least two or three previous sternoto-
mies and are known to be high-risk candidates for heart transplan-
tation. Beyond these excellent results in a difficult patient popu-
lation, they have elucidated an interesting finding regarding PVR
in the patients. They found that cardiac transplantation unmasked
pulmonary vascular disease not evident at pretransplantation as-
sessment.
I have three questions, Dr Mitchell. My first question relates to
the decision process for the patient with failing Fontan circulation
and atrial arrhythmias. I noticed in your series that at least 4 of the
patients with late Fontan circulation failure had atrial flutter as part
of their transplantation indications. We now have 60 patients at
Children’s Memorial Hospital who have undergone Fontan con-
version with arrhythmia surgery. In that series, 7 patients were
actually initially referred for heart transplantation. In our 60 Fon-
tan conversions, we’ve had an operative mortality of 2%, and 4
patients have required late cardiac transplantation between 8 days
and 33 months after the conversion operation. When should we
recommend cardiac transplantation, and when should we recom-
mend Fontan conversion with arrhythmia surgery?
My second question relates to your uncovering of the under-
estimation of PVR before transplantation. What criteria would you
use for declaring a patient not a candidate for cardiac transplan-
tation on the basis of PVR in the presence of a functioning Fontan
circulation?
My final question relates to the etiology of the elevated PVR.
Some groups believe that the administration of warfarin decreases
the incidence of chronic microemboli through the years, which
might contribute to keeping the PVR low. What role do you think
the administration of warfarin has for the patient with a Fontan
circulation? Were your patients treated with warfarin, and what do
you think about this particular theory in light of your interesting
data?
Dr Mitchell. First, I would say that transplantation is a last
resort for these patients, and patients that are deemed to be good
candidates for conversion with or without arrhythmia surgery
should undergo that as opposed to transplantation. Having said
that, in our series there were 4 patients with atrial flutter; 3 of those
700 The Journal of Thoracic and Cardiovascular Surgery ● Nove4 also had PLE, and the other patient already had a previous
conversion to an extracardiac conduit. So I think that few if any of
those patients would have been good candidates to go on to
another conversion procedure.
I would say that the information from your group—which is
remarkable, the results have been just spectacular in terms of
mortality in particular—is something that we’ve taken to heart
during the last several years. Most of these patients actually had
their transplants well before your results were published, so we
have begun to look much more strongly at that option for several
patients we’ve seen recently. Having said that, I’m not certain that
from our data we can tell you when you should transplant and
when you should do a conversion. I suspect that you probably have
far greater experience in terms of how to determine when the
ventricular function will respond to an atrial conversion or to
correction of atrial arrhythmias. So when do we transplant? One of
the problems with these patients is that they tend to percolate along
fairly stably and then have a relatively rapid demise. So I think that
waiting too long will increase the mortality. An early approach is
probably favorable, and that’s certainly something that we have
tried to do. We try to make a decision early on in their process as
to whether to go toward transplantation or try to nurse them along.
You asked what the criteria should be in terms of PVR in these
patients. And I think that probably one of the more surprising
findings for us is that the TPGs were really depressed at the
pretransplantation evaluation. We have typically used a TPG of 20
mm Hg as the absolute maximum, which is a bit higher; some
groups have said to use 15 mm Hg. I think that in this population
it should probably be lower, because we have certainly seen a
marked increase in the real TPG after surgery.
Finally, you asked about warfarin as a treatment for these
patients I think is probably warranted. Microemboli certainly may
underlie some of the increased PVR if this is a real phenomenon,
although there are a number of other possible reasons that the
Fontan circulation itself might increase PVR. I don’t think warfa-
rin in and of itself is the only answer.
Dr John A. Hawkins (Salt Lake City, Utah). These are great
results in a very difficult group of patients. My question has to do
with a phenomenon that I believe very few of us in this room can
directly experience, and that is the Fontan procedure at high
altitude. How much of your findings do you think may be due to
the fact that these were patients who underwent a Fontan proce-
dure and subsequently remained at high altitude for some time?
How might that have affected your PVR or TPG? Would you
obtain these same findings in a patient with a Fontan procedure at
low altitude or at sea level?
Dr Mitchell. I can only speculate on that. For one thing, about
40% of these patients were referred from elsewhere, so their
Fontan procedures and much of their palliative life had not been
spent at the altitude at which we live. On the other hand, if you
extrapolate what is known from normal patients to this population,
it certainly is cause for concern. For example, the normal mean
PAP measured at sea level, and most of this is from work done in
the 1960s, is roughly 12 to 13 mm Hg, whereas people at the
University of Colorado determined in the 1960s that mean PAP in
Denver is about 16 mm Hg. So there is a small incremental
increase in that 5000 feet of increased elevation. But if you take
patients at 10,000 feet, such as in Leadville, Colo, the mean PAP
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Dis 24 mm Hg. So there is an increase above the altitude that Salt
Lake City lies at and a more substantial increase above Denver, so
that there is probably a greater impact on the patients that truly live
in the mountains versus the patients at the more moderate levels at
which we live. Beyond that, I really think this is an area for
investigation in which we are certainly interested.
Dr Gil Wernovsky (Philadelphia, Pa). This was a terrific
presentation. First, I have a similar question in terms of where the
patients lived and for how long. Did you have those data before
and then after transplantation?
Second, do you have any similar data on, say, patients with
cardiomyopathy? Is there something unique about the transplant
itself that changes TPG or PVR in patients who may have started
with a biventricular circulation?
Dr Mitchell. Taking your second question first, we have not
looked at that yet in patients with cardiomyopathy. I considered
trying to do that as a control group, but I think that chronic
elevation of left atrial pressure itself can induce pulmonary vas-
cular disease. Therefore, patients with cardiomyopathy who have
much worse ventricular function than these patients are probably
not an appropriate control group, which is why we looked at
normal values versus the abnormal.
Please remind me of your first question.
Dr Wernovsky. I was wondering if you had any of the demo-
graphic data on the patients, and would you recommend that they
can now move back to Denver, whereas they might have been
living down at sea level because of their Fontan state?
Dr Mitchell. I don’t have that information. I can tell you that
40% were treated previously and either moved to Denver or were
directly referred to Denver for transplantation. In a series this
small, I’m not sure what we could really learn, except to tell you
that there is a strong bias among the cardiologists in our region to
encourage these patients to live at sea level if at all possible.
Dr Wernovsky. Were the pretransplantation evaluations done
in Denver, or were the catheterization data from other institutions?
Dr Mitchell. With the exception of I think 2 patients, all
evaluations were done in our institution. One evaluation was done
outside the area and 1 was done in another institution in Denver.
Dr Francois Lacour-Gayet (Denver, Colo). I take the freedom
to discuss this paper from Denver, as I have nothing to do with this
wonderful result. As I have discussed before, I think this is
probably the first article to prove, attempt to prove, or even suspect
that the mode of failure of the Fontan circulation in the long term
can be elevation of PVR. It could be that living at a high altitude
can increase this phenomenon.
I know how long you spend on your data. Please give us your
feeling about this interesting proof that came out from your study.
Dr Mitchell. I hesitate to say that we proved that the Fontan
creates an increase in PVR, and I think that we’re very limited in
our ability to do so. I’ve looked at the prepalliation data that we
were able to obtain, which unfortunately is in quite a minority of
cases, but I can tell you that the prepalliation mean PAP in the
patients for whom we had data was 5 mm Hg lower than their
pretransplantation data. That, in combination with the length of
palliation these patients had and their finding that the only those
with normal PVR had early failure, is suggestive that the Fontan
circulation itself may increase PVR, but it is clearly not proof.
The Journal of ThoraciThe second thing that I would say is that we had enough
difficulty relying on the pretransplantation assessments, and it is
even more difficult to calculate an accurate PVR in a patient before
palliation because of so many of the anatomic and multiple sources
of collateral flow that are often present in those patients.
Dr Michal Wojtalik (Poznan, Poland). Fontan pulmonary
circulation is an area of nonpulsatile flow lasting for a very long
time, and introduction of pulsatile flow might cause a kind of
limitation of the vasculature. Do you think that this is why the PVR
rises?
Dr Mitchell. I think exactly the opposite, and it is not my
thinking, it is from writing from authorities in this field. The
coupling of the right ventricle to the pulmonary artery and the
energy imparted into the pulmonary vasculature by a pulsatile
system is necessary to keep the distal pulmonary tree open. Having
had the absence of that for their entire lives and then having the
introduction of pulsatile energetic flow into the pulmonary arteries,
it doesn’t seem that that process was reversed in these patients,
which is what I would have expected. I think that there is some
fixed element of disease that’s brought out by the increased energy
and the increased cardiac output in those patients.
Dr Thomas L. Spray (Philadelphia, Pa). You have really hit
on the fundamental question here. Is this resistance fixed, or is it
going to change with time? If it is a reintroduction of pulsatile flow
and you can remodel the distal vasculature, then theoretically, the
PVR should potentially decrease with time. If it’s related to throm-
boembolism, presumably it is fixed and will not remodel.
Did you do any kind of manipulations in the catheterization
laboratory to look and see whether there was any reactivity to this
PVR in the posttransplantation period, and did you follow up the
patients sequentially during the posttransplantation interval to see
whether there was any change in their PVR?
Dr Mitchell. We did not look at reactivity, primarily because
when these studies were done it wasn’t even a consideration. The
studies were done as part of posttransplantation surveillance, pri-
marily looking for rejection. Looking at the patients who’ve un-
dergone serial examinations, if anything, what we’ve seen in many
of them is a progressive increase in PVR. There were very few in
whom it had fallen. What I have noted is that patients who have
had problems with rejection or who have had significant CAD and
have late-failing Fontan circulations tend to be the ones with the
increasing PVR. As far as how much of this is fixed, we have no
data to really be able to comment on that. When I say “fixed,” I just
mean the simple introduction of increased flow manifests an in-
creased TPG without any attempt at pulmonary vasodilation or
anything to really assess for what we would traditionally be talking
about in reactivity.
Dr W. Steves Ring (Dallas, Tex). One of the other things you
might consider is the role of the immunosuppressant agents, par-
ticularly the calcineurin inhibitors such as cyclosporine (INN:
ciclosporin), which are known to cause increased systemic vascu-
lar resistance and also have some minor, lesser effects on PVR.
This could explain a lot of the changes that you’ve seen, irrespec-
tive of the Fontan physiology.
Dr Mitchell. I think that’s a good point. I wasn’t aware of their
direct effect on the vasculature. There is simply no way I think we
can separate out the influence of transplantation versus the influ-
ence of the previous disease process, except to say that I attempted
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Dto look at pathologic processes in the few patients who eventually
died. Among those patients, we were able to come up with tissue
in 1 case, and that patient did have medial muscular hypertrophy
I don’t know what the mechanism behind calcineurin702 The Journal of Thoracic and Cardiovascular Surgery ● Novenisms are behind the changes in patients with Fontan circulation,
but we are not talking about large magnitudes of pulmonary
vascular disease. The point is, in this patient population, it doesn’t
take a lot, most likely, to create problems; whereas in a normalinhibitors is, and we certainly don’t know what the mecha- biventricular circulation, this level of disease is well tolerated.mber 2004
